166 related articles for article (PubMed ID: 18623377)
21. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.
Engelhardt BG; Holland DW; Brandt SJ; Chinratanalab W; Goodman SA; Greer JP; Jagasia MH; Kassim AA; Morgan DS; Ruffner KL; Schuening FG; Wolff S; Bitting R; Sulur P; Stein RS
Leuk Lymphoma; 2007 Sep; 48(9):1728-35. PubMed ID: 17786708
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.
Maeng CH; Ko YH; Lim DH; Kang ES; Choi JY; Kim WS; Kim SJ
Cancer Res Treat; 2017 Jan; 49(1):92-103. PubMed ID: 27188204
[TBL] [Abstract][Full Text] [Related]
23. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
25. Stem cell transplantation in Hodgkin lymphoma.
Reddy NM; Perales MA
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1097-112. PubMed ID: 25459181
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.
Moskowitz CH; Kewalramani T; Nimer SD; Gonzalez M; Zelenetz AD; Yahalom J
Br J Haematol; 2004 Mar; 124(5):645-52. PubMed ID: 14871252
[TBL] [Abstract][Full Text] [Related]
27. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
28. High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience.
Dowling AJ; Prince HM; Wirth A; Wolf M; Januszewicz EH; Juneja S; Seymour JF; Gates P; Smith JG
Intern Med J; 2001 Jul; 31(5):279-89. PubMed ID: 11512599
[TBL] [Abstract][Full Text] [Related]
29. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
[TBL] [Abstract][Full Text] [Related]
30. High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China.
Xie Y; Wang X; Leng X; Zheng W; Ping L; Zhang C; Liu W; Deng L; Wu M; Song Y; Zhu J
Ann Hematol; 2020 Mar; 99(3):549-555. PubMed ID: 31980860
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
32. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
33. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
34. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Argiris A; Seropian S; Cooper DL
Ann Oncol; 2000 Jun; 11(6):665-72. PubMed ID: 10942053
[TBL] [Abstract][Full Text] [Related]
35. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
36. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A
Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830
[TBL] [Abstract][Full Text] [Related]
37. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
[TBL] [Abstract][Full Text] [Related]
38. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors.
Re A; Michieli M; Casari S; Allione B; Cattaneo C; Rupolo M; Spina M; Manuele R; Vaccher E; Mazzucato M; Abbruzzese L; Ferremi P; Carosi G; Tirelli U; Rossi G
Blood; 2009 Aug; 114(7):1306-13. PubMed ID: 19451551
[TBL] [Abstract][Full Text] [Related]
39. Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study.
Gao L; Xiang X; Zhang C; Gao L; Yang T; Wang S; Li B; Lou S; Yi Su ; Liu Y; Zhang X
Hematology; 2019 Dec; 24(1):225-231. PubMed ID: 31081725
[TBL] [Abstract][Full Text] [Related]
40. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
Lavoie JC; Connors JM; Phillips GL; Reece DE; Barnett MJ; Forrest DL; Gascoyne RD; Hogge DE; Nantel SH; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Voss NJ; Nevill TJ
Blood; 2005 Aug; 106(4):1473-8. PubMed ID: 15870180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
